Oncology Pharma Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- George Malesek
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Sansome Street San Francisco CA United States of America 94104
- IPO Date
- Oct 31, 1994
- Website
- oncology-pharma.com
- Similar Companies
- Business
- Oncology Pharma Inc. (ONPH) is an oncology-focused biotechnology company that licenses, develops, manufactures and commercializes therapeutics targeting various cancers including breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia. The company offers NanoSmart platform technology featuring a patented human-derived antinuclear antibody for targeted delivery of lipid nanoparticle-encapsulated doxorubicin to necrotic areas in solid tumors; Connect2Med smartphone app for clinical trial patient recruitment and support; small molecule modulators of NR2F6 activity from KCL Therapeutics for colon cancer treatment; and antigen-specific mRNA cellular cancer vaccine from Regen Biopharma targeting pancreatic cancer via survivin-derived epitopes. Founded in 1993 and headquartered at 1 Sansome Street, Suite 3500, San Francisco, California, Oncology Pharma operates primarily in the United States with a single employee and maintains a collaboration with Kalos Therapeutics to explore COVID-19 treatments. The company rebranded from SourcingLink.net Inc. in June 2019 and continues advancing its nanoemulsion drug delivery systems, including dactinomycin formulations for pediatric and orphan indications, with ongoing investor discussions for further development as of 2022.
Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR)
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
Shares of This Biotech Stock Could Jump 437%
Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
This Biotech Stock Could Jump +500%
Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange
Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer
Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform
Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology
RGBP Stock: Why Little-Known Regen Biopharma Is Soaring 800% Today
Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer
Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities
Oncology Pharma Reveals Strategic Plans for Company Growth and Focus
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent
Oncology Pharma Renews Licensing Agreement With Ribera Solutions LLC for Its Connect2Med Clinical Trials Platform